Abstract
Background - Hemophilia, a rare bleeding disorder, raises significant pharmacoeconomic challenges, particularly with the emergence of innovative therapies. This study evaluates clinical and patient-reported outcomes and expenditures in hemophilia patients focusing on those who underwent therapeutic switches between 2017 and 2023.
Materials and methods - This retrospective study included severe hemophilia patients. Expenditure was analyzed based on clotting factor consumption, while clinical well-being was assessed using ABR, NRS for pain, joint health scores (HJHS, HEAD-US) and trough plasma levels. A sub-analysis was conducted by applying different therapeutic groups. Statistical significance of differences between paired measures (pre [T0] vs post [T1]) was examined using the Wilcoxon Sum Rank test.
Results - Seventy patients were included. Total expenditure was € 12,947,580.44 in 2017 and € 12,967,576.92 in 2023. Among 45 patients who switched therapy, the median number of infusions/year significantly decreased from 156 to 91 (p<0.001), ABR from 1 to 0 (p<0.001) and NRS from 3,5 to 0 (p<0.001). Joint health did not show improvement with a slight but not statistically significant increase (HJHS from 10 to 15; HEAD-US from 7 to 8). Median trough increased from 3 IU/mL to 5 IU/mL (p=0.181). Patients were grouped for analysis based on homogeneous treatment regimens.
Discussion - This study is the first effort to conduct comprehensive analysis of the impact of therapeutic choices on well-being and cost of care in hemophilia Center. The study underscores the need for a value-based approach to hemophilia care, integrating expenditure and clinical outcomes. Adopting validated economic weight outcome in future pharmacoeconomic evaluations will be essential for decision making.
References
pdf
Authors
Carola Sella
Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; Division of Hematology, AOU Città della Salute e della Scienza, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Federica Valeri
Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; Division of Hematology, AOU Città della Salute e della Scienza, Turin, Italy
Cristina Dainese
Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; Division of Hematology, AOU Città della Salute e della Scienza, Turin, Italy
Annamaria Porreca
Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Open University, Rome, Italy; Unit of Clinical and Molecular Epidemiology IRCCS San Raffaele, Roma, Rome, Italy
Matilde Scaldaferri
Department of Quality and Safety of Care, Pharmacy, AOU Città della Salute e della Scienza, Turin, Italy
Daniela Cestino Department of Quality and Safety of Care, Pharmacy, AOU Città della Salute e della Scienza, Turin, Italy
Roberta Aldieri Department of Quality and Safety of Care, Pharmacy, AOU Città della Salute e della Scienza, Turin, Italy
Giulia Soave Department of Quality and Safety of Care, Pharmacy, AOU Città della Salute e della Scienza, Turin, Italy
Sara Bergonzi
Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; Division of Hematology, AOU Città della Salute e della Scienza, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Giovanni Murante Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; Division of Hematology, AOU Città della Salute e della Scienza, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Rebecca Pastorino
Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; Division of Hematology, AOU Città della Salute e della Scienza, Turin, Italy
Alessandra Valpreda Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Turin, Italy
Benedetto Bruno Division of Hematology, AOU Città della Salute e della Scienza, Turin, Italy; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Alessandra Borchiellini
Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; Division of Hematology, AOU Città della Salute e della Scienza, Turin, Italy
- Abstract viewed - 643 times
- pdf downloaded - 0 times